Please login to the form below

Not currently logged in
Email:
Password:

patient access

This page shows the latest patient access news and features for those working in and with pharma, biotech and healthcare.

Novartis first to benefit from NICE advice on ‘patient preference’

Novartis first to benefit from NICE advice on ‘patient preference’

The advice was provided to Novartis, and looked at a patient preference study for people with respiratory condition chronic obstructive pulmonary disease (COPD). ... Nigel Cook, Head of Decision Support &Insights, Global Patient Access at Novartis

Latest news

  • Industry aghast as EU Parliament backs biosimilar rule change Industry aghast as EU Parliament backs biosimilar rule change

    Our industry is extremely concerned that the proposal for the SPC manufacturing waiver will put patient access to medical innovation, highly killed jobs and investment at risk,” writes Oschmann. ... while stimulating greater access to medicines at

  • UK patient activist group takes aim at Orkambi patent UK patient activist group takes aim at Orkambi patent

    The push for compulsory licensing has been driven by a newly-formed patient activist group called Just Treatment. ... Vertex issued a statement on Friday, saying it was “determined to find a solution” that allows the NHS to provide patient access to

  • Hardy returns to Genentech as CEO Hardy returns to Genentech as CEO

    Alexander Hardy (pictured below) will take the helm of Genentech in March, having previously held several senior management positions at the Roche-owned company, including head of patient access services.

  • NICE gives Lilly’s Verzenios chance to compete with rivals NICE gives Lilly’s Verzenios chance to compete with rivals

    Lilly got the green light after improving its price offering via a revised patient access scheme, and NICE says it is now cost effective relative to the other treatments in the ... Crucially, this drug’s availability will now help improve patient choice

  • Drug pricing is pharma’s top concern in 2019 Drug pricing is pharma’s top concern in 2019

    The move is being resisted fiercely by industry bodies including PhRMA, which says in its comments that it would “lead to significant barriers and delays in patient access to clinically important ... Conversations with payers will also be a lot tougher

More from news
Approximately 0 fully matching, plus 416 partially matching documents found.

Latest Intelligence

  • Immunotherapy combination trials Q&A Immunotherapy combination trials Q&A

    In particular, what approaches should be taken in regards to patient recruitment for these trials? ... This provides access to a broader patient pool. However a focus on increased support for the community-based centres is paramount to achieve success.

  • Why precision medicine demands precision engagement Why precision medicine demands precision engagement

    The treatable patient population is also expanding, growing three-fold every three years. ... New technologies will make it simpler to access, extract and use aggregated patient data in new ways in order to develop and align targeted treatments.

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    a medicine is no longer economic to supply and where discontinuation would have a negative impact on patient health. ... There is no conceivable scenario in which any government would accept the political risk of reducing the threshold: every patient

  • Launch like a PRO: the art and science of successful entry to market Launch like a PRO: the art and science of successful entry to market

    From strategy to project management, market access to public affairs, governance to HEOR, they provide an incredibly thorough test of an organisation’s capability. ... Read any article on launch and the chances are it will major on patient-centricity,

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    Most notably, fast patient access for CAR-T cell therapies, Gilead’s Yescarta and Novartis’ Kymriah, where England has been ahead of its European counterparts in making the drugs available. ... For this new environment, we need people who understand

More from intelligence
Approximately 2 fully matching, plus 87 partially matching documents found.

Latest appointments

  • ProPharma selects new CEO and president ProPharma selects new CEO and president

    She has also held the role of chief operating officer for Teva Pharmaceuticals, where her focus included strategy and innovation for patient solutions, commercial effectiveness, market access, business insights and market

  • Therachon poaches Shire’s Aled Williams Therachon poaches Shire’s Aled Williams

    He becomes the biotech’s chief commercial officer and head of patient access. ... Therachon, a clinical-stage biotechnology company, has appointed Aled Williams to the position of chief commercial officer and head of patient access.

  • Open Health creates new role Open Health creates new role

    In order to strengthen their experience and expertise, healthcare communications and market access group Open Health has appointed Gavin Jones into its newly formed role of director of rare disease. ... Joining the agency with twenty years’

  • Mereo BioPharma appoints head of patient access and commercial planning Mereo BioPharma appoints head of patient access and commercial planning

    Her new role will see her take responsibility for leading and optimising Mereo’s patient access and commercialisation strategies, initially on a part-time basis as the company builds out its ... Most recently, Hughes-Wilson served on the executive

  • Sobi names Holly May VP of sales and marketing, US Sobi names Holly May VP of sales and marketing, US

    She will work with the biopharma’s commercial and patient access teams. ... She will also collaborate with the operations and patient access team to ensure the medicines are accessible to as many appropriate patients and she will support the launch of

More from appointments
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest from PMHub

  • NHS Long Term Plan - Digital is firmly on the agenda. Are you ready?

    The NHS App will create a standard online way for people to access the NHS. ... The app will work seamlessly with other services at national and local levels and, where appropriate, be integrated into patient pathways.

  • Artificial Intelligence in Healthcare

    NHS’s doors to strike deals for access to patient information. ... a patient’s list of regular medicines, which then have to be dictated or faxed.

  • Practical Patient Centricity

    In our experience, companies typically have three key reasons to embrace patient centricity:. ... Patient centricity is the next market access – and will take 10 years to embed”.

  • Solaris Health looks at the gene therapy revolution

    a real-life scenario and how patient access will be managed. ... But, of course, low patient numbers can also result in huge risk for manufacturers.

  • More tell, less sell: HCP-centric comms

    One example has been the shift in the balance of the HCP–patient relationship. ... With regard to the old hat approach of providing only product-related information, HCPs state that they would be more interested in being able to access dosing

More from PMHub
Approximately 0 fully matching, plus 48 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics